Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2022-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司关于2021年日常关联交易执行情况及2022年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the execution of related party transactions for the year 2021 and the forecast for 2022 by Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details about the nature of the transactions, amounts involved, related parties, pricing policies, and approvals by the board and independent directors. The document is structured as a formal announcement to shareholders and the public about related party transactions, their compliance with regulations, and the company's governance around these transactions. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a full audit report or earnings release. The document is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure and does not fit other more specific categories.
2022-04-25 Chinese
独立董事对担保等事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various company matters including the 2021 profit distribution plan, internal control self-evaluation report, appointment of the audit firm for 2022, short-term risk investment, external guarantees and related party transactions. It references compliance with regulatory guidelines and company bylaws, and provides independent opinions on these governance and financial oversight matters. The document does not contain full financial statements or detailed financial results, but rather independent directors' opinions on governance and audit-related issues. This type of document is typically classified as a Regulatory Filing (RNS) because it is a compliance and governance-related disclosure rather than a full annual report, audit report, or other specific financial report. The document length is under 5,000 characters and it is not a report publication announcement but a formal opinion statement by independent directors.
2022-04-25 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the eighth board of directors of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes approval of the 2021 annual report and summary, 2021 board work report, 2021 general manager work report, 2021 financial final accounts report, 2021 profit distribution plan, internal control evaluation report, social responsibility report, appointment of the audit firm for 2022, 2022 first quarter report, related party transactions, use of funds for short-term risk investment, and proposal to convene the 2021 annual general meeting. The document is a formal board meeting resolution announcement, not the actual annual report or financial statements themselves. It is a regulatory announcement of board decisions and proposals to be submitted to the shareholders' meeting for approval. The document length is 3510 characters, relatively short and mainly contains meeting resolutions and voting results. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and management reports approval, rather than the full annual report or financial statements themselves.
2022-04-25 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized report issued by an accounting firm (Da Hua Certified Public Accountants) regarding the use of funds by controlling shareholders and related parties of Beijing SL Pharmaceutical Co., Ltd. It references the audit of the 2021 financial statements and provides a special explanation on non-operating fund occupation and related party transactions as required by Chinese securities regulatory authorities. The document includes detailed financial data and tables related to these transactions, and it is not a general annual report or earnings release. It is a standalone audit-related report focusing on a specific regulatory requirement about related party fund usage, which fits the definition of an Audit Report / Information (AR). The document length (8545 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-25 Chinese
北京双鹭药业股份有限公司监事会对公司2021内部控制评价报告的意见
Audit Report / Information Classification · 95% confidence The document is an opinion statement from the Supervisory Board regarding the company's 2021 internal control evaluation report. It references regulatory guidelines and confirms the effectiveness of internal controls for the year 2021. The document is short (467 characters) and does not contain detailed financial data or the full internal control report itself, but rather an opinion on that report. This fits best under Audit Report / Information (AR), which includes audit reports and internal control evaluations, rather than a full Annual Report or Regulatory Filing. Therefore, the classification is AR with high confidence. FY 2021
2022-04-25 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, shareholding changes, bond information, and a full financial report section. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial statements and signatures from company officers and auditors, confirming it is the official comprehensive yearly report covering company activity and full financial performance for the fiscal year 2021. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-04-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.